Literature DB >> 15892598

Increased mRNA expression of VEGF within the hematoma and imbalance of angiopoietin-1 and -2 mRNA within the neomembranes of chronic subdural hematoma.

Axel Hohenstein1, Ralf Erber, Lothar Schilling, Ralf Weigel.   

Abstract

The aim of the study was to determine the source of vascular endothelial growth factor (VEGF) in hematoma fluid of patients suffering from chronic subdural hematoma (CSH) and to identify the level of gene expression of the pro-angiogenic factors angiopoietin 1 (ANG-1) and ANG-2 in hematoma membranes. Samples of venous blood, hematoma fluid, and outer membrane were obtained during surgery for CSH. The numbers of mononuclear cells were determined in hematoma fluid and in venous blood samples taken from 11 patients. The concentration of VEGF was measured by ELISA technique in hematoma fluid and in plasma. RT-PCR methodology was used to study the expression of different mRNA species in 11 patients. The mRNA species analyzed include VEGF and its receptors, VEGFR-1 and VEGFR-2, and ANG-1, ANG-2 and their receptor, Tie-2. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as housekeeping gene and was used for semiquantitative analysis. The VEGF concentration was several hundred fold higher in the hematoma fluid than in corresponding plasma samples. A significant correlation was found between the number of neutrophils and the VEGF content in the hematoma fluid. The expression levels of VEGF, mainly VEGF165 and VEGF121 mRNA were highest in cells obtained from the hematoma fluid. In membrane samples, mRNA encoding for VEGF and its receptors was only inconsistently detected while the mRNA species encoding for ANG-1, ANG-2, and Tie-2 were found throughout all samples. The mean ratio of ANG-1/ANG-2 mRNA expression was 0.48 as opposed to 1.9 in a normal human brain tissue sample. The results suggest that the hematoma cells are the primary source of VEGF. A marked increase in the expression of ANG-2 mRNA over ANG-1 mRNA demonstrates a pro-angiogenic pattern in the hematoma membranes. Persistent activation of the ANG/Tie-2 system in addition to high levels of VEGF may keep the vasculature in a destabilized condition and may account for the continuous formation of new and immature blood vessels resulting in massive plasma extravasation and repeated bleeding episodes. Thus, the present study provides new evidence in favor of pro-angiogenic mechanisms playing an important role in the pathophysiology of CSH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15892598     DOI: 10.1089/neu.2005.22.518

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  30 in total

1.  Local and systemic pro-inflammatory and anti-inflammatory cytokine patterns in patients with chronic subdural hematoma: a prospective study.

Authors:  Milo Stanisic; Ansgar Oddne Aasen; Are Hugo Pripp; Karl-Fredrik Lindegaard; Jon Ramm-Pettersen; Staale Petter Lyngstadaas; Jugoslav Ivanovic; Ane Konglund; Eivind Ilstad; Tiril Sandell; Omar Ellingsen; Terje Sæhle
Journal:  Inflamm Res       Date:  2012-04-19       Impact factor: 4.575

2.  Role of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, and Vascular Endothelial Growth Factor in the Development of Chronic Subdural Hematoma.

Authors:  Cong Hua; Gang Zhao; Yan Feng; Hongyan Yuan; Hongmei Song; Li Bie
Journal:  J Neurotrauma       Date:  2015-08-06       Impact factor: 5.269

Review 3.  Membranectomy in Chronic Subdural Hematoma: Meta-Analysis.

Authors:  Ronald Sahyouni; Hossein Mahboubi; Peter Tran; John S Roufail; Jefferson W Chen
Journal:  World Neurosurg       Date:  2017-05-13       Impact factor: 2.104

Review 4.  Chronic Subdural Hematoma: A Perspective on Subdural Membranes and Dementia.

Authors:  Ronald Sahyouni; Khodayar Goshtasbi; Amin Mahmoodi; Diem Kieu Tran; Jefferson W Chen
Journal:  World Neurosurg       Date:  2017-09-19       Impact factor: 2.104

5.  Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial.

Authors:  Rongcai Jiang; Shiguang Zhao; Renzhi Wang; Hua Feng; Jianmin Zhang; Xingang Li; Ying Mao; Xianrui Yuan; Zhou Fei; Yuanli Zhao; Xinguang Yu; Wai Sang Poon; Xide Zhu; Ning Liu; Dezhi Kang; Tao Sun; Baohua Jiao; Xianzhi Liu; Rutong Yu; Junyi Zhang; Guodong Gao; Jiehe Hao; Ning Su; Gangfeng Yin; Xingen Zhu; Yicheng Lu; Junji Wei; Jin Hu; Rong Hu; Jianrong Li; Dong Wang; Huijie Wei; Ye Tian; Ping Lei; Jing-Fei Dong; Jianning Zhang
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

6.  An association of low high-density lipoprotein levels with recurrence of chronic subdural hematoma.

Authors:  Wen-Chao Liu; Qing-Qing Lin; Jing Jin; Ming Wang; Wen-Dong You; Jun Gu; Jian-Wei Pan
Journal:  Acta Neurochir (Wien)       Date:  2020-11-04       Impact factor: 2.216

7.  Vascular endothelial growth factor concentration in chronic subdural hematoma fluid is related to computed tomography appearance and exudation rate.

Authors:  Ralf Weigel; Axel Hohenstein; Lothar Schilling
Journal:  J Neurotrauma       Date:  2014-01-17       Impact factor: 5.269

8.  Impact of inflammatory cell ratio, biomarkers, activated partial thromboplastin time and prothrombin time on chronic subdural haematoma severity and outcome.

Authors:  Olufemi Emmanuel Idowu; Stevens Olaide Oyeleke; Julius Mautin Vitowanu
Journal:  Eur J Trauma Emerg Surg       Date:  2021-04-11       Impact factor: 3.693

9.  Statins as a Medical Adjunct in the Surgical Management of Chronic Subdural Hematomas.

Authors:  Bradley S Guidry; Katherine A Kelly; Aaron M Yengo-Kahn; Matthews Lan; Alan R Tang; Silky Chotai; Peter Morone; Patrick D Kelly
Journal:  World Neurosurg       Date:  2021-02-18       Impact factor: 2.104

10.  Update in the treatment of traumatic brain injury.

Authors:  Scott E Bell; Roman Hlatky
Journal:  Curr Treat Options Neurol       Date:  2006-03       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.